Arsenal Medical

Arsenal Medical leverages a proprietary biomaterials platform to create transformative medical devices for critical care in neurovascular and trauma settings. Its lead programs include ResQFoam, an FDA Breakthrough Device for abdominal hemorrhage control, and NeoCast, an injectable material for deep neurovascular occlusion, which has completed a First-in-Human study. The company is backed by prestigious scientific founders, a seasoned management team, and has secured significant non-dilutive funding from government agencies, positioning it to advance its pipeline through clinical development.

Proprietary biomaterials platform engineering materials with specific physical/chemical properties (e.g., shear-thinning, rapid expansion) for therapeutic functions like hemorrhage control and vascular occlusion, delivered via minimally invasive methods.

In trauma, Arsenal competes with other hemostatic agents, gauzes, and devices for internal hemorrhage, but ResQFoam's mechanism of action appears distinct. In neurovascular embolization, NeoCast would compete against established liquid embolics (e.g., Onyx), coils, and particles. Differentiation hinges on its deep penetration and material properties.